Unfortunately, not all patients attain such a favorable response. Primary or secondary resistance, defined at the hematological level, may develop in ∼4% of chronic phase cases, whereas cytogenetic ...
The ACCENT database, with individual patient data for 20 898 patients from 18 colon cancer clinical trials, was used to support Food and Drug Administration (FDA) approval of 3-year disease-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results